Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib-Reference-Cited by-同舟云学术

Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib

Published:2014-02-06 Issue:4 Volume:57 Page:1170-1187
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Huang Qinhua¹,Johnson Ted W.¹,Bailey Simon¹,Brooun Alexei¹,Bunker Kevin D.¹,Burke Benjamin J.¹,Collins Michael R.¹,Cook Andrew S.¹,Cui J. Jean¹,Dack Kevin N.¹,Deal Judith G.¹,Deng Ya-Li¹,Dinh Dac¹,Engstrom Lars D.¹,He Mingying¹,Hoffman Jacqui¹,Hoffman Robert L.¹,Johnson Patrick S.¹,Kania Robert S.¹,Lam Hieu¹,Lam Justine L.¹,Le Phuong T.¹,Li Qiuhua¹,Lingardo Laura¹,Liu Wei¹,Lu Melissa West¹,McTigue Michele¹,Palmer Cynthia L.¹,Richardson Paul F.¹,Sach Neal W.¹,Shen Hong¹,Smeal Tod¹,Smith Graham L.¹,Stewart Albert E.¹,Timofeevski Sergei¹,Tsaparikos Konstantinos¹,Wang Hui¹,Zhu Huichun¹,Zhu Jinjiang¹,Zou Helen Y.¹,Edwards Martin P.¹

Affiliation:

1. La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm401805h

Reference49 articles.

1. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)

2. Behavioral and Neurochemical Alterations in Mice Deficient in Anaplastic Lymphoma Kinase Suggest Therapeutic Potential for Psychiatric Indications

3. The anaplastic lymphoma kinase in the pathogenesis of cancer